JP2024540304A5 - - Google Patents

Info

Publication number
JP2024540304A5
JP2024540304A5 JP2024526616A JP2024526616A JP2024540304A5 JP 2024540304 A5 JP2024540304 A5 JP 2024540304A5 JP 2024526616 A JP2024526616 A JP 2024526616A JP 2024526616 A JP2024526616 A JP 2024526616A JP 2024540304 A5 JP2024540304 A5 JP 2024540304A5
Authority
JP
Japan
Prior art keywords
approximately
day
administration
administered
combination according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024526616A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540304A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/060616 external-priority patent/WO2023079494A1/en
Publication of JP2024540304A publication Critical patent/JP2024540304A/ja
Publication of JP2024540304A5 publication Critical patent/JP2024540304A5/ja
Pending legal-status Critical Current

Links

JP2024526616A 2021-11-03 2022-11-03 抗cd38抗体による治療におけるコルチコステロイドの減少 Pending JP2024540304A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163275157P 2021-11-03 2021-11-03
US63/275,157 2021-11-03
US202163280791P 2021-11-18 2021-11-18
US63/280,791 2021-11-18
US202163288785P 2021-12-13 2021-12-13
US63/288,785 2021-12-13
US202263394726P 2022-08-03 2022-08-03
US63/394,726 2022-08-03
PCT/IB2022/060616 WO2023079494A1 (en) 2021-11-03 2022-11-03 Corticosteriod reduction in treatment with anti-cd38 antibodies

Publications (2)

Publication Number Publication Date
JP2024540304A JP2024540304A (ja) 2024-10-31
JP2024540304A5 true JP2024540304A5 (enExample) 2025-11-11

Family

ID=84361138

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526616A Pending JP2024540304A (ja) 2021-11-03 2022-11-03 抗cd38抗体による治療におけるコルチコステロイドの減少

Country Status (11)

Country Link
US (2) US20230136301A1 (enExample)
EP (1) EP4426435A1 (enExample)
JP (1) JP2024540304A (enExample)
KR (1) KR20240099411A (enExample)
AU (1) AU2022380155A1 (enExample)
CA (1) CA3237175A1 (enExample)
CL (1) CL2024001324A1 (enExample)
IL (1) IL312514A (enExample)
JO (1) JOP20240106A1 (enExample)
MX (1) MX2024005406A (enExample)
WO (1) WO2023079494A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024360739A1 (en) * 2023-10-12 2026-04-02 Janssen Biotech, Inc. Methods for treating multiple myeloma comprising an anti-cd38 antibody combined with bortezomib, lenalidomide and dexamethasone

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
NZ542873A (en) 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
KR20140066259A (ko) 2004-02-06 2014-05-30 모르포시스 아게 항-cd38 인간 항체 및 그의 용도
JP5225069B2 (ja) 2005-03-23 2013-07-03 ゲンマブ エー/エス 多発性骨髄腫の治療のためのcd38に対する抗体
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
CA2625681C (en) 2005-10-12 2016-08-02 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
RU2766608C2 (ru) 2012-04-11 2022-03-15 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
BR112015027313A2 (pt) 2013-04-29 2017-09-26 Teva Pharmaceuticals Australia Pty Ltd anticorpos anti-cd38 e fusões ao interferon alfa-2b atenuado
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
ES2878449T3 (es) 2014-07-24 2021-11-18 2Seventy Bio Inc Receptores antigénicos quiméricos de BCMA
CN118271463A (zh) 2014-12-05 2024-07-02 纪念斯隆-凯特琳癌症中心 靶向g-蛋白偶联受体的嵌合抗原受体及其用途
HRP20191873T1 (hr) 2014-12-12 2020-01-24 Bluebird Bio, Inc. Kimerni antigenski receptori
EA201792546A1 (ru) * 2015-05-20 2018-04-30 Янссен Байотек, Инк. Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2018028647A1 (en) 2016-08-10 2018-02-15 Legend Biotech Usa Inc. Chimeric antigen receptors targeting bcma and methods of use thereof
MX2018002043A (es) 2015-08-17 2018-07-06 Janssen Pharmaceutica Nv ANTICUERPOS ANTI-BCMA, MOLí‰CULAS DE UNIí“N A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.
DE102016211884A1 (de) 2016-06-30 2018-01-04 Zf Friedrichshafen Ag Getriebe für ein Kraftfahrzeug, sowie Antriebsstrang für ein Kraftfahrzeug
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗gprc5d抗體、結合gprc5d與cd3之雙特異性抗原結合分子及其用途
US20200017600A1 (en) 2018-07-13 2020-01-16 Genmab A/S Variants of cd38 antibody and uses thereof
KR20210077725A (ko) * 2018-10-17 2021-06-25 얀센 바이오테크 인코포레이티드 항-cd38 항체의 피하 투여를 제공하는 방법
BR112021013824A2 (pt) 2019-01-18 2021-12-14 Janssen Biotech Inc Receptores de antígeno quiméricos gprc5d e células que expressam os mesmos
US20200308297A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses

Similar Documents

Publication Publication Date Title
CN102811730B (zh) 孕激素作为糖皮质激素增敏剂的使用
JP2025102775A5 (enExample)
JP2021534201A5 (enExample)
JP2022538237A5 (enExample)
Marrani et al. Long-term efficacy of abatacept in pediatric patients with idiopathic uveitis: a case series
Rasheed et al. A review of natural steroids and their applications
JP2024518947A5 (enExample)
JP2024129140A5 (enExample)
JP2019514974A5 (enExample)
JP2024540304A5 (enExample)
Jiang et al. Novel use of dupilumab in pemphigus vulgaris and pemphigus foliaceus
JP2025072466A5 (enExample)
JPWO2020250915A5 (enExample)
Helfer et al. Corticosteroids and adrenal suppression: characterising and avoiding the problem
JP2024537288A5 (enExample)
US6096731A (en) Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation
JP2022537555A5 (enExample)
JP2024543509A5 (enExample)
IL312514A (en) Corticosteroid reduction in treatment with anti-cd38 antibodies
IL312515A (en) Bispecific cd16a binders
Sandborn Steroid‐Dependent Crohn’s Disease
Myers Treatment of multiple sclerosis with ACTH and corticosteroids
WO2020106191A1 (ru) Производное глутаримида для преодоления резистентности к стероидам
JP2024516886A5 (enExample)
JP2021505545A5 (enExample)